186 related articles for article (PubMed ID: 36424008)
1. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
Kishima H; Mine T; Fukuhara E; Kitagaki R; Asakura M; Ishihara M
JACC Clin Electrophysiol; 2022 Nov; 8(11):1393-1404. PubMed ID: 36424008
[TBL] [Abstract][Full Text] [Related]
2. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis.
Zhao Z; Jiang C; He L; Zheng S; Wang Y; Gao M; Lai Y; Zhang J; Li M; Dai W; Zuo S; Guo X; Li S; Jiang C; Liu N; Tang R; Long D; Du X; Sang C; Dong J; Ma C
J Am Heart Assoc; 2023 Dec; 12(24):e031269. PubMed ID: 38084708
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients.
Liu HT; Wo HT; Chang PC; Lee HL; Wen MS; Chou CC
Heliyon; 2023 Jun; 9(6):e16835. PubMed ID: 37332966
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
5. Cryoablation for paroxysmal and persistent AF in patients with structural heart disease and preserved ejection fraction: Clinical outcomes from 1STOP, a multicenter observational project.
Perego GB; Iacopino S; Molon G; Arena G; Verlato R; Pieragnoli P; Curnis A; Allocca G; Nicolis D; Sciarra L; Catanzariti D; Senatore G; Rovaris G; Brasca F; Tondo C;
J Cardiol; 2019 Jul; 74(1):19-26. PubMed ID: 30948185
[TBL] [Abstract][Full Text] [Related]
6. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
Luo F; Sun L; Wang Z; Zhang Y; Li J; Chen Y; Dong J
Cardiovasc Drugs Ther; 2024 Feb; 38(1):91-98. PubMed ID: 35962156
[TBL] [Abstract][Full Text] [Related]
8. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes.
Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S
JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953
[TBL] [Abstract][Full Text] [Related]
9. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on outcomes of catheter ablation for atrial fibrillation.
Deshmukh A; Ghannam M; Liang J; Saeed M; Cunnane R; Ghanbari H; Latchamsetty R; Crawford T; Batul SA; Chung E; Bogun F; Jongnarangsin K; Pelosi F; Chugh A; Morady F; Oral E; Oral H
J Cardiovasc Electrophysiol; 2021 May; 32(5):1232-1239. PubMed ID: 33600005
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
12. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
13. Left atrial ejection force predicts the outcome after catheter ablation for paroxysmal atrial fibrillation.
Kishima H; Mine T; Takahashi S; Ashida K; Ishihara M; Masuyama T
J Cardiovasc Electrophysiol; 2018 Feb; 29(2):264-271. PubMed ID: 29125704
[TBL] [Abstract][Full Text] [Related]
14. Catheter ablation of persistent atrial fibrillation with and without a history of paroxysmal atrial fibrillation.
Miao CL; Yin XD; Dong JZ; Liu XP; Yu RH; Long DY; Tang RB; Sang CH; Ma CS
Chin Med J (Engl); 2012 Mar; 125(6):1175-8. PubMed ID: 22613550
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation.
Takigawa M; Takahashi A; Kuwahara T; Okubo K; Takahashi Y; Watari Y; Takagi K; Fujino T; Kimura S; Hikita H; Tomita M; Hirao K; Isobe M
Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):267-73. PubMed ID: 24610740
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
[TBL] [Abstract][Full Text] [Related]
17. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study.
Bhargava M; Di Biase L; Mohanty P; Prasad S; Martin DO; Williams-Andrews M; Wazni OM; Burkhardt JD; Cummings JE; Khaykin Y; Verma A; Hao S; Beheiry S; Hongo R; Rossillo A; Raviele A; Bonso A; Themistoclakis S; Stewart K; Saliba WI; Schweikert RA; Natale A
Heart Rhythm; 2009 Oct; 6(10):1403-12. PubMed ID: 19716348
[TBL] [Abstract][Full Text] [Related]
18. Right atrial diameter and outcome of catheter ablation of atrial fibrillation.
Wen S-; Liu N; Bai R; Tang RB; Yu RH; Long DY; Sang CH; Jiang CX; Li SN; Wu JH; Ruan YF; Hu R; Du X; Liu XH; Dong JZ; Ma CS
J Interv Card Electrophysiol; 2017 Aug; 49(2):157-164. PubMed ID: 28612230
[TBL] [Abstract][Full Text] [Related]
19. Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
Yamabe H; Kaikita K; Matsumura T; Iwasa A; Koyama J; Uemura T; Morikami Y; Tsunoda R; Morihisa K; Fujimoto K; Kajiwara I; Matsui K; Tsujita K; Ogawa H
J Cardiol; 2018 Feb; 71(2):129-134. PubMed ID: 28886992
[TBL] [Abstract][Full Text] [Related]
20. Cryoballoon versus radiofrequency for pulmonary vein re-isolation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation.
Pokushalov E; Romanov A; Artyomenko S; Baranova V; Losik D; Bairamova S; Karaskov A; Mittal S; Steinberg JS
J Cardiovasc Electrophysiol; 2013 Mar; 24(3):274-9. PubMed ID: 23210695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
